FDA 483 - Baxter SA - September 27, 2019

An FDA inspection conducted at Baxter SA in Lessines, Belgium, from September 19 to September 27, 2019, identified significant deviations from current Good Manufacturing Practices (cGMP). The manufacturer received an FDA Form 483 citing nine observations primarily related to inadequate quality control and laboratory operations. Key issues included a lack of documented investigations for out-of-specification results and invalidated tests, with no proper trending for root cause analysis. Analysts demonstrated poor aseptic technique and gowning during critical sterility and bioburden testing, raising concerns about product integrity. The firm's environmental monitoring procedures lacked sufficient detail and consistency, and waste management practices in the sterility laboratory obstructed ventilation. Furthermore, Baxter SA failed to adequately monitor and evaluate defective units from both process validation and routine manufacturing for potential process control trends. Deviations from written production and process control procedures were observed, such as shortened visual inspection times. Laboratory records contained unjustified manual corrections, and a critical employee's GMP training record was missing. These observations indicate a need for comprehensive corrective and preventive actions across Baxter SA's quality management system, laboratory controls, manufacturing processes, and personnel training to ensure compliance with regulatory requirements and maintain product quality and safety.